Drugs / LUTETIUM LU 177 ZADAVOTIDE GURAXETAN
LUTETIUM LU 177 ZADAVOTIDE GURAXETAN
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03874884 | Jul 2019 → May 2025 overdue | prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06361810 | Oct 2025 → Jan 2031 | clear cell renal carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05230251 | Mar 2022 → Sep 2023 | prostate cancer | Glenn Bauman | Completed | No outcome recorded |
| Phase 1/2 | NCT03658447 | Jul 2019 → Dec 2022 | castration-resistant prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06322576 | Feb → Nov 2025 | adenoid cystic carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT06259123 | Feb 2024 → Jan 2027 expected | prostate cancer | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 2 | NCT06220188 | Jan 2024 → Jun 2026 overdue | prostate cancer | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 2 | NCT05560659 | Dec 2023 → May 2026 overdue | metastatic prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Recruiting | No outcome recorded |
| Phase 2 | NCT05893381 | Jun 2023 → Sep 2027 expected | prostate cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting | No outcome recorded |
| Phase 2 | NCT05867615 | May 2023 → Aug 2026 overdue | cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05496959 | Sep 2022 → Sep 2032 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04647526 | Feb 2021 → Nov 2023 overdue | castration-resistant prostate carcinoma | POINT Biopharma | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06033001 | — | castration-resistant prostate carcinoma | Lantheus Medical Imaging | Temporarily not available | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUTETIUM LU 177 ZADAVOTIDE GURAXETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314936 ↗ |
| Known as | 177Lu-PNT2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06322576 ↗ |
| Known as | 177Lu-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05560659 ↗ |
| Known as | [177Lu]Lu-PNT2002 | “INTRODUCTION: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [177Lu]Lu-PNT2002 radioligand therapy in metastatic...” PMID 39839782 ↗ Jan 2025 |
| Known as | [177Lu]Lu-PSMA I&T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05893381 ↗ |
| Known as | [Lu-177]-PNT2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06033001 ↗ |
| Known as | Lutetium Lu-177 PNT2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496959 ↗ |
| Known as | Pnt2002 lu-177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314936 ↗ |
| Known as | Zadavotide guraxetan lutetium lu-177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314936 ↗ |
| Action | Inhibit | “a small molecule inhibitor of PSMA” NCT05560659 ↗ |
| Modality | Other / unclassified | “radioligand therapy” PMID 39839782 ↗ Jan 2025 |
| Route | Intravenous | “[177Lu]Lu-PSMA-617 intravenously every 6 weeks” PMID 41926961 ↗ Apr 2026 |